What's in FRESENIUS KABI USA's pipeline?

FRESENIUS KABI USA has 4 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with FRESENIUS KABI USA's portfolio?

Top competitors by shared drug class: , Amgen, EVIVE BIOTECHNOLOGY, Berlex Labs, CELLTRION INC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fresenius-kabi-usa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-01 · How we verify

FRESENIUS KABI USA — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FRESENIUS KABI USA pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
OTULFI	USTEKINUMAB-AAUZ	marketed	Interleukin-12 Antagonist [EPC]	Other
STIMUFEND	PEGFILGRASTIM-FPGK	marketed	Leukocyte Growth Factor [EPC]	Other
IDACIO	ADALIMUMAB-AACF	marketed		Other
TYENNE	TOCILIZUMAB-AAZG	marketed	Interleukin-6 Receptor Antagonist [EPC]	Other

Therapeutic area mix

Other · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 2 shared drug classes
Amgen · 1 shared drug class
EVIVE BIOTECHNOLOGY · 1 shared drug class
Berlex Labs · 1 shared drug class
CELLTRION INC · 1 shared drug class
CELLTRION, INC. · 1 shared drug class
BIOGEN MA · 1 shared drug class
AMGEN INC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for FRESENIUS KABI USA:

Cite this brief

Drug Landscape (2026). FRESENIUS KABI USA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fresenius-kabi-usa. Accessed 2026-06-01.